Skip to main content
Clinical Trials/NCT02340559
NCT02340559
Completed
Not Applicable

Effectiveness of Meta-Cognitive Training (EMC) on Symptmos, Metacognition, Social and Neuropsychological Functioning in People With Psychosis of Brief Evolution

Fundació Sant Joan de Déu0 sites122 target enrollmentAugust 2012
ConditionsPsychosis

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Psychosis
Sponsor
Fundació Sant Joan de Déu
Enrollment
122
Primary Endpoint
PANSS. Positive and Negative Syndrome Scale
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

The purpose of this study is to assess the effectiveness of Meta-Cognitive Training (EMC) in people with a brief psychotic disorder, especially positive symptoms.

The secondary objectives would be to assess the effect of EMC on metacognition (cognitive distortions and deficits in theory of mind), psychosocial functioning and quality of life, neuropsychological functioning and gender, as well as determine the changes produced by EMC in the insight of each session and the maintenance of the effects of EMC program at six months of treatment.

Detailed Description

The study is a randomized clinical trial in which a group will receive the Meta-Cognitive Training (EMC) and a control group will receive a journal workshop. The evaluator will be blind to the group that owns the patients included. The total simple will be of 122 people with a psychotic disorder, less than 5 years of evolution and a score at or above 3 on the PANSS during the last year. Patients should be attended in one of the next services: Parc Sanitari Sant Joan de Déu, Corporació Sanitària Parc Taulí, Hospital de la Santa Creu i Sant Pau, Hospital Clínic de Valencia, Centre d´Higiene Mental de les Corts, Institut d´Assitència Sanitària Girona, Servicio Andaluz de Granada, Málaga y Jaén. The assessment was performed at baseline, at the end of treatment and six month follow-up. The assessment includes: psychopathology and insight ( PANSS, PSYRATS, PDI, GAF, BDI, BCIS, Sumd), meta-cognition (jumping to conclusions, IPSAQ, TCI), neuropsychology (WCST, TMT, CPT-II, TAVEC, WAIS) and social functioning and quality of life (EFS, DAS-SV, SLDS). The insight will be assessed at the final of each session (BCIS). The treatment and control group consist of 8 weekly sessions of 45-60 minutes with a total of 4 to 8 patients per group. The EMC group material is translated and validated in Spanish by investigators of the team. The primary analysis variable is the difference between the scores of experimental and control group in the symptoms scales (especially positive). Secondary outcomes will change in other assessments of social functioning, metacognition (cognitive distortions and theory of mind) and neuropsychological variables. Were analyzed using regression and ANCOVA methods with SPSS 19.

Registry
clinicaltrials.gov
Start Date
August 2012
End Date
December 2014
Last Updated
11 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of : schizophrenia, schizoaffective disorder, brief psychotic disorder, delusional disorder, schizophreniform disorder, psychotic disorder not otherwise specified.
  • Less than 5 years of evolution.
  • Score at or above 4 on the PANSS during the last year (delusions, grandiosity, suspiciousness).

Exclusion Criteria

  • Neurological disorder which impairs cognition.
  • Intellectual Disability.
  • Score at or above 5 on the PANSS ( Hostility and Uncooperativeness); score at or above 6 on the PANSS (suspiciousness).

Outcomes

Primary Outcomes

PANSS. Positive and Negative Syndrome Scale

Time Frame: baseline, 2 months (post-treatment) and 6 months of follow-up

The Positive and Negative Syndrome Scale (PANSS)(Kay et al., 1987; Peralta and Cuesta, 1994) measures 30 symptoms on a scale of 1-7, with higher scores indicating greater psychopathology. The PANSS contains three sub-scales: positive, negative and general symptoms.

PSYRATS. Psychotic Symptoms Rating Scale

Time Frame: baseline, 2 months (post-treatment) and 6 months of follow-up

The PSYRATS (Haddock et al, 1999; Gonzalez et al, 2003). This scale assess delusions in 6 items.

Secondary Outcomes

  • Jumping to conclusions(baseline, 2 months (post-treatment) and 6 months of follow-up)
  • BCIS. Beck Cognitive and Insight Scale(baseline, 2 months (post-treatment) and 6 months of follow-up. Moreover in the intervention group this scale was assessed at the end of each session)
  • IPSAQ. Internal, Personal and Situational Attribution Questionnaire.(baseline, 2 months (post-treatment) and 6 months of follow-up.)
  • Hinking Task(baseline, 2 months (post-treatment) and 6 months of follow-up.)
  • TCI scale "Test de Creencias Irracionales"(baseline, 2 months (post-treatment) and 6 months of follow-up.)

Similar Trials